https://www.selleckchem.com/pr....oducts/acalabrutinib
To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC). This multicenter placebo-controlled double-blind randomized phase III trial (ClinicalTrials.gov identifier NCT0303810 enrolled patients with newly diagnosed untreated International Federation of Gynecology and Obstetrics (FIGO) stage III or IV OC who either had undergone primary cytoreductive surgery with macroscop
Like
Comment
Share
